We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for gilteritinib (as fumarate) (Astellas Pharma Australia Pty Ltd)
Active ingredients
gilteritinib (as fumarate)
Date of review outcome
Lapse date
Type
Priority review
Dosage form(s)
Film-coated tablet
Indication
gilteritinib (as fumarate) is indicated for the treatment of adult patients who have relasped or refactory acute myeloid leukemia (AML) with a FLT3 mutation.
Therapeutic area
Haematology